Program-2022

Program is subject to change. 

Workshop Pretest

Completed online between Saturday, July 23 and Sunday, July 24

SUNDAY, JULY 24

Shuttles from Denver International Airport
11:30 am-2:00 pm / 12:30 pm-3:00 pm / 1:15 pm-3:45 pm

Registration
1:30 pm-5:30 pm

Faculty Meeting
4:45 pm-5:30 pm

Welcome/Overview
5:30 pm-5:45 pm

Manuel Hidalgo, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York

Opening Keynote Lecture
Session Chair: Manuel Hidalgo, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY
5:45 pm-6:30 pm

William G. Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts

Dinner
6:30 pm-7:15 pm

Protocol Development Group Session
6:30 pm-9:00 pm

MONDAY, JULY 25

Breakfast
7:00 am-8:00 am

Lecture Session 1
Session Chair: Julie M. Vose, University of Nebraska Medical Center, Omaha, Nebraska
8:00 am-10:00 am

  • Clinical Trial Design: Asking Important Questions that Impact Our Patients
    Julie M. Vose, University of Nebraska Medical Center, Omaha, Nebraska
  • Answering Important Questions: From Hypothesis to Analysis
    Thomas M. Braun, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
  • Phase I Trial Questions
    Manuel Hidalgo, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York
  • Phase I Trial Designs
    Nolan M. Wages, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia

Questions / Panel Discussion

Break
10:00 am-10:20 am

Lecture Session 2
Session Chair: Mary W. Redman, Fred Hutchinson Cancer Research Center, Seattle, Washington
10:30 am-12:45 pm

  • Phase II Trial Questions/Objectives
    Maha Hussain, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • Phase II Trial Designs
    Sean Devlin, Memorial Sloan Kettering Cancer Center, New York, New York
  • Novel Trial Designs
    Mary W. Redman, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • Drug Combination Trials
    Yelena Janjigian, Memorial Sloan Kettering, New York, New York
  • Multimodality Trials
    Karyn Goodman, Icahn School of Medicine at Mount Sinai, New York, New York

Questions / Panel Discussion

Lunch (boxed)
12:45 pm-1:30 pm

Protocol Development Group 2
1:30 pm-4:00 pm

Independent Study Time
4:00 pm-7:00 pm

Office Hours 1 (Biostatisticians; appointments will be scheduled by PDG faculty)
4:30 pm-6:30 pm

ASSIGNMENT DUE: PROTOCOL TEMPLATE
7:00 pm

Dinner
7:00 pm-9:00 pm

TUESDAY, JULY 26

Breakfast
7:00 am-8:00 am

Special Lecture
8:00 am-8:30 am

Career Development Opportunities: The Government Can Help
Oliver Bogler, National Cancer Institute, Rockville, Maryland

Lecture Session 3
Session Chair: Wendy B. London, Boston Children’s Hospital/Dana-Farber Cancer Institute Boston, Massachusetts
8:30 am-10:00 am

  • Feasibility and Reproducibility in Biomarker Studies
    Kurt A. Schalper, Yale University, New Haven, Connecticut
  • Incorporation of Biological Correlative Studies into Early Clinical Trials
    Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Statistical Aspects of Correlative Studies
    Wendy B. London, Boston Children’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

Questions / Panel Discussion

Break
10:00 am-10:30 am

Lecture Session 4
Session Chair: Ezra Cohen, UCSD Moores Cancer Center, La Jolla, California
10:30 am-12:00 pm

  • Imaging in the Era of Targeted Therapy and Immunotherapy
    Thomas E. Yankeelov, The University of Texas, Austin, Texas
  • Special Considerations in the Design of Immunotherapy Studies
    Alex A. Adjei, Cleveland Clinic, Cleveland, Ohio
  • Inflammatory and Immunologic Biomarkers
    Ezra Cohen, UCSD Moores Cancer Center, La Jolla, California

Questions / Panel Discussion

Lunch (boxed)
12:00 pm-12:45pm

Protocol Development Group Session 3
12:45 pm-3:45 pm

Break
3:45 pm-4:00 pm

Office Hours 2: Protocol Related Questions
4:00 pm-6:00 pm

Independent Study Time
3:45 pm-7:00 pm
Pizza and salads available from 5:00 pm-7:00 pm

ASSIGNMENT DUE: STATISTICAL DESIGN
7:00 pm

WEDNESDAY, JULY 27

Breakfast
7:00 am-8:00 am

Small Group Discussion Sessions 1-3
8:00 am-9:00 am

  • Artificial Intelligence
    Thomas E. Yankeelov, The University of Texas, Austin, Texas
  • Palliative Care and Quality of Life
    Dawn L. Hershman, Herbert Irving Comprehensive Cancer Center of Columbia University, New York, New York
    Shing Lee, Columbia University, New York, New York
    Patient Advocate to be announced
  • Phase III Trials
    Lindsay Renfro, University of Southern California, Los Angeles, California
    Elizabeth Plimack, Fox Chanse Cancer Center, Philadelphia, Pennsylvania
    Patient Advocate to be announced

Break
9:00 am-9:15 am

Small Group Discussion Sessions 4-6
9:15 am-10:15 am

  • Navigating the National Clinical Trials Network
    Speaker to be announced
    Vijay Bhatt, Univeristy of Nebraska Medical Center, Omaha, Nebraska
  • Incorporation of Digital Health and PROs
    Karyn Goodman, Icahn School of Medicine at Mount Sinai, New York, New York
    Sujata Patil, The Cleveland Clinic, Cleveland, Ohio
    Patient Advocate to be announced
  • Laboratory Correlates
    Elizabeth G. Hill, Hollings Cancer Center at the Medical University of South Carolina, Charleston, South Carolina
    Ruth O’Regan, University of Rochester, Rochester, New York
    Kurt A. Schalper, Yale University, New Haven, Connecticut

Break / Group Photo
10:15 am-10:30 am

Small Group Discussion Sessions 7-9
10:30 am-11:30 am

  • Defining, Identifying, and Knowing Your Trial’s Clinical Endpoints
    John Byrd, University of Cincinnati College of Medicine, Cincinnati, Ohio
    Chen Hu, Johns Hopkins University, Baltimore, Maryland
    Patient Advocate to be announced
  • First in Human Trials: Understanding the Regulatory Process
    Franklin Smith, Medpace, Cincinnati, Ohio
    Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
  • Large-Scale Genomic Analysis: Bench to Bedside
    Manish Shah, Weill Cornell Medical College, New York, New York
    Tim Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

Lunch
11:30 am-12:30 pm

Lecture Session 5
Session Chair: Thomas Braun, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
12:30 pm-2:00 pm

  • Leveraging Large Datasets in Clinical Trial Design
    Thomas Braun, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
  • Barriers to Accrual and How to Overcome Them
    Ruth O’Regan, University of Rochester, Rochester, New York
  • Research Challenges and Lessons Learned in the era of COVID
    Laura C. Michaelis, Medical College of Wisconsin, Milwaukee, Wisconsin

Questions / Panel Discussion

Break
2:00 pm-2:15 pm

Protocol Development Group Session 4
2:15 pm-4:15 pm

Independent Study Time/Dinner on Own
4:15 pm-7:00 pm

ASSIGNMENT DUE: PROTOCOL DRAFTS
7:00 pm

THURSDAY, JULY 28

Breakfast
7:00 am-8:00 am

Lecture Session 6
Session Chair: Manish A. Shah, Weill Cornell Medical College, New York, New York
8:00 am-9:40 am

  • You’re In Charge: Investigator Responsibilities
    Manish A. Shah, Weill Cornell Medical College, New York, New York
  • How to Pay For Your Trial
    Doug Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
  • Everything You Need to Know About Clinical Trial Ethics and Informed Consent: A Case Study
    Dawn L. Hershman, Herbert Irving Comprehensive Cancer Center of Columbia University, New York, New York
    Ivy B. Elkins, EGFR Resisters, Evanston, Illinois
    Patient Advocate to be announced

Questions / Panel Discussion

Break
9:40 am-9:55 am

Lecture Session 7
Session Chair: Mark Krailo, Children’s Oncology Group, Arcadia, California
9:55 am-11:35 am

  • Data Collection: It’s All In the Data
    Mark Krailo, Children’s Oncology Group, Arcadia, California
  • Inclusivity in Clinical Trials
    Stuart M. Lichtman, Memorial Sloan Kettering Cancer Center, New York, New York
    Josh Mailman, NorCal CarciNET Community, Oakland, California

Questions / Panel Discussion

Break
11:35 am-11:45 am

Keynote Lecture
11:45 am-12:35 pm

Monica Bertagnolli, Brigham and Women’s Hospital, Boston, Massachusetts

Lunch
12:35 pm-1:30 pm

Protocol Development Group Session 5
1:30 pm-3:00 pm

Independent Study Time/Dinner on Own
3:00 pm-7:00 pm

Office Hours 3
3:30 pm-5:00 pm

Optional Networking Session: Women in Hematology/Oncology
5:15 pm-6:15 pm

ASSIGNMENT DUE: INFORMED CONSENT DOCUMENTS
7:00 pm

FRIDAY, JULY 29

Breakfast
7:00 am-8:30 am

Faculty Meeting (Faculty Only)
7:30 am-8:30 am

Optional Career Sessions
8:30 am-9:30 am

  • Collaborating with Industry
    Maura Dickler, Eli Lilly and Company, Indianapolis, Indiana
    Franklin O. Smith, Medpace, Cincinnati, Ohio
  • Careers in Radiation Oncology
    Jeff Bogart, State University of New York, Albany, New York
    Adam Dicker, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, Pennsylvania
  • Career Transition Tips
    Faculty to be announced

Break
9:30 am-9:45 am

Lecture Session 8
Session Chair: Alex A. Adjei, Cleveland Clinic, Cleveland, Ohio
9:45 am-11:30 am

  • Successful Grantsmanship
    Dawn L. Hershman, Herbert Irving Comprehensive Cancer Center of Columbia University, New York, New York
  • Reporting and Presenting Results
    Shing Lee, Columbia University, New York, New York
    Tari King, Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center, Boston, Massachusetts

Questions / Panel Discussion

Break
11:10 am-11:20 pm

Protocol Development Group Session 6
11:20 am-1:00 pm

Lunch (box)
1:00 pm-1:30 pm

Administration of Post-test
1:30 pm-2:30 pm

Independent Study Time
2:30 pm-7:00 pm

ASSIGNMENT DUE: FINAL PROTOCOLS, INFORMED CONSENT FORMS, and ALL WORKSHOP EVALUATIONS
7:00 pm

Closing Reception / Banquet / Dance
7:00 pm-11:00 pm

SATURDAY, JULY 30

Continental Breakfast
5:00 am-8:00 am

Departure
6:00 am-8:30 am / 7:15 am-9:45 am / 10:00 am-12:30 pm